Eylea (Aflibercept) is a new FDA approved drug developed for the treatment of wet age-related macular degeneration (wet AMD). Age-related macular degeneration (AMD) is an eye condition that causes damage to the macula, a small area in the retina responsible for the sharp central vision that allows you to see fine details clearly. It is a leading cause of blindness and is most common in individuals above 50 years of age.
ILUVIEN is a corticosteroid micro-implant that is injected into the centre of the eyeball, which is known as the vitreous cavity, to help reduce swelling, improve vision, and alleviate eye pain in patients with diabetic macular oedema who have been treated with corticosteroids in the past without having significant increased intraocular pressure.
An intravitreal injection is a non-invasive eye procedure where medication is injected into the vitreous cavity - the space at the back of your eyes, near the retina. The vitreous cavity is filled with vitreous humour gel, a jelly-like fluid.